Newsroom
New real-world data show potential of Trilaciclib to reduce the substantial burden of myelosuppression in patients with extensive-stage small-cell lung cancer treated with chemotherapy
Written by
Integra Connect
| Mar 31, 2022 9:00:00 PM
Click here to
read the original article at G1 Therapeutics
.
View full post